trending Market Intelligence /marketintelligence/en/news-insights/trending/qH_o_rVO7j8OYSodKpmmrg2 content esgSubNav
In This List

Mallinckrodt to sell drug portflio for $171M

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Mallinckrodt to sell drug portflio for $171M

Piramal Enterprises Ltd. is acquiring a portfolio of intrathecal spasticity and pain management drugs from Mallinckrodt.

The company will pay $171 million for the assets, which include Gablofen and two pain management products under development.

Piramal will also pay another $32 million depending on the financial performance of the acquired assets.

Gablofen, a severe spasticity management product, is marketed in the U.S. and is approved for launch in eight European markets.

The transaction is subject to U.S. regulatory review and certain other closing conditions.